

Codex Genetics, C2N to launch Alzheimer's blood test in Hong Kong

11 March 2026 | News

The partnership will introduce the PrecivityAD2™ blood test to healthcare professionals across Hong Kong



Codex Genetics, a leading precision diagnostics company headquartered in Hong Kong, has announced a strategic collaboration with C2N Diagnostics, a global leader in advanced brain health diagnostics.

The partnership will introduce the PrecivityAD2™ blood test to healthcare professionals across Hong Kong, enabling access to C2N's innovative technology that aids in the diagnosis of Alzheimer's disease.

The PrecivityAD2™ test is intended for individuals aged 50 years and older with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer's disease or other causes of cognitive decline. The PrecivityAD2™ test detects the presence or absence of brain amyloid pathology, a key hallmark of Alzheimer's disease, and supports a clinician's diagnosis.

Using high-resolution mass spectrometry, the PrecivityAD2™ test measures the plasma amyloid beta (A β 42/40) ratio and the percentage of phosphorylated tau at threonine-217 (%p-tau217) and combines into a proprietary algorithm that yields a clear Positive or Negative result indicating a high or low likelihood of amyloid plaque presence.

Alzheimer's disease represents a growing public health concern in Hong Kong and across Asia amid aging populations. Among community-dwelling older adults in Hong Kong, approximately 20% have mild neurocognitive impairment and 7.4% are affected by major neurocognitive disorders (dementia), with prevalence increasing sharply with age.